ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
Fudan University
Bayer
Virginia Commonwealth University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BigHat Biosciences, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
InnoPharmax Inc.
Memorial Sloan Kettering Cancer Center
University of Miami
M.D. Anderson Cancer Center
Fudan University
Gilead Sciences
Fundació d'investigació Sanità ria de les Illes Balears
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Guangdong Provincial People's Hospital
Shanghai Shengdi Pharmaceutical Co., Ltd
Stanford University
Tongji Hospital
Virogin Biotech Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
AbbVie
Massachusetts General Hospital
Tianjin Medical University Cancer Institute and Hospital
Pfizer
Shanghai Jiao Tong University School of Medicine
University Hospital, Caen
Catholic University of the Sacred Heart
Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai Zhongshan Hospital
Asan Medical Center
Asan Medical Center
Sir Run Run Shaw Hospital
Tianjin Medical University Cancer Institute and Hospital
Fudan University
West China Hospital
Zhongnan Hospital
Centre hospitalier de l'Université de Montréal (CHUM)
Chang Gung Memorial Hospital
Korea University Anam Hospital
OHSU Knight Cancer Institute
Nanfang Hospital, Southern Medical University
Centre Leon Berard
M.D. Anderson Cancer Center
Shanghai 10th People's Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Novartis
Sun Yat-sen University